YorkBridge Wealth Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

YorkBridge Wealth Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$421K	Sell	3,702 -333	-8%	-$27.7K	0.11%	144
2022 Q3	$250K	Buy	4,035 +351	+10%	+$24.5K	0.06%	233
2022 Q2	$294K	Sell	3,684 -161	-4%	-$15.2K	0.08%	201
2022 Q1	$405K	Sell	3,845 -97	-2%	-$9.45K	0.09%	174
2021 Q4	$425K	Buy	3,942 +60	+2%	+$6.54K	0.1%	174
2021 Q3	$425K	Buy	3,882 +167	+4%	+$17.3K	0.11%	148
2021 Q2	$348K	Buy	3,715 +16	+0.4%	+$1.47K	0.09%	182
2021 Q1	$340K	Buy	+3,699	New	+$312K	0.1%	172
2019 Q3	–	Sell	-365	Closed	-$9K	–	757
2019 Q2	$9K	Sell	365 -196	-35%	-$4.97K	﹤0.01%	599
2019 Q1	$15K	Sell	561 -484	-46%	-$11.5K	0.01%	510
2018 Q4	$20K	Sell	1,045 -251	-19%	-$4.92K	0.01%	469
2018 Q3	$24K	Buy	+1,296	New	+$24.6K	0.01%	488

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

YorkBridge Wealth Partners's HZNP Position: Q4 2022 in Review

YorkBridge Wealth Partners reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 8.3% in Q4 2022, selling an estimated $27.7K and leaving 3,702 shares worth $421K. The position accounts for 0.11% of the portfolio, ranked #144.

YorkBridge Wealth Partners first reported a position in HZNP in Q3 2018 and has held it in 12 quarters since. The position peaked at $425K in Q4 2021. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

YorkBridge Wealth Partners held 3,702 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $421K as of Q4 2022.
YorkBridge Wealth Partners sold 333 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $27.7K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.11% of YorkBridge Wealth Partners's portfolio in Q4 2022, its #144 holding.
YorkBridge Wealth Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and has held it in 12 quarters since.
YorkBridge Wealth Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $425K in Q4 2021.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on YorkBridge Wealth Partners's 13F filing for Q4 2022, filed 26 Jan 2023.